SCHEMBL13637468

SCHEMBL13637468

Cc1cccc(CNS(=O)(=O)c2cccc(CBr)c2)c1

nearest known ligand 0.64

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
CYP19A1 P11511 8/20 0.64
KMT2A Q03164 1/20 0.56
ALDH1A1 P00352 1/20 0.55
CYP1A2 P05177 2/20 0.54
CYP3A4 P08684 2/20 0.54
CA12 O43570 1/20 0.54
ATM Q13315 1/20 0.54
CA9 Q16790 1/20 0.54
L3MBTL1 Q9Y468 1/20 0.54
CYP2C19 P33261 1/20 0.53
TP53 P04637 3/20 0.52
POLB P06746 1/20 0.52
FBP1 P09467 1/20 0.51
MAPT P10636 1/20 0.50
AKR1C3 P42330 1/20 0.50
KEAP1 Q14145 1/20 0.49
NAMPT P43490 1/20 0.48
LMNA P02545 2/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4661682 0.85 CYP19A1 (0.71) CYP19A1KMT2AALDH1A1CYP1A2CYP3A4
SCHEMBL13637461 0.82 CYP19A1 (0.59) CYP19A1KMT2AALDH1A1CYP1A2CYP3A4
SCHEMBL16660687 0.82 ALDH1A1 (0.73) CYP19A1KMT2AALDH1A1CYP1A2CYP3A4
SCHEMBL13637458 0.81 ALDH1A1 (0.60) CYP19A1KMT2AALDH1A1CYP1A2CYP3A4
SCHEMBL14049658 0.80 AKR1C3 (0.59) CYP19A1ALDH1A1CYP2C19MAPTAKR1C3
SCHEMBL13628247 0.79 NAMPT (0.55) CYP19A1ALDH1A1POLBMAPTNAMPT
SCHEMBL14902026 0.78 KMT2A (0.62) CYP19A1KMT2AALDH1A1CYP1A2CYP3A4
SCHEMBL2462774 0.77 L3MBTL1 (0.47) CYP19A1KMT2AALDH1A1L3MBTL1POLB
SCHEMBL3564279 0.76 CYP19A1 (0.67) CYP19A1CYP1A2CYP3A4CA12ATM
SCHEMBL12530468 0.76 KMT2A (0.59) CYP19A1KMT2AALDH1A1CYP1A2CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090275583-A1 ANTIVIRAL COMPOUNDS AND USE THEREOF MYRIAD GENETICS, INCORPORATED (US) 2009-11-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090275583-A1 ANTIVIRAL COMPOUNDS AND USE THEREOF MAVS, ZC3HAV1, EIF2AK2 CYP19A1 3957/4885KMT2A 4125/4885ALDH1A1 2676/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.